TWI464148B - 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 - Google Patents

Info

Publication number

TWI464148B

TWI464148B TW096108752A TW96108752A TWI464148B TW I464148 B TWI464148 B TW I464148B TW 096108752 A TW096108752 A TW 096108752A TW 96108752 A TW96108752 A TW 96108752A TW I464148 B TWI464148 B TW I464148B

Authority

TW

Taiwan

Prior art keywords

isoquinolin

dihydro

hydroxy

phenyl

methyl

Prior art date

2006-03-16

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 367
• -1 bicyclic heteroaryl compound Chemical class 0.000 claims description 196
• 238000006243 chemical reaction Methods 0.000 claims description 134
• 125000003118 aryl group Chemical group 0.000 claims description 96
• 125000000217 alkyl group Chemical group 0.000 claims description 92
• 150000003839 salts Chemical class 0.000 claims description 89
• 229910052739 hydrogen Inorganic materials 0.000 claims description 77
• 239000001257 hydrogen Substances 0.000 claims description 75
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 70
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 67
• 208000024891 symptom Diseases 0.000 claims description 67
• 201000010099 disease Diseases 0.000 claims description 62
• 125000001072 heteroaryl group Chemical group 0.000 claims description 49
• 125000001424 substituent group Chemical group 0.000 claims description 49
• 150000001412 amines Chemical class 0.000 claims description 44
• 229910052736 halogen Inorganic materials 0.000 claims description 43
• 150000002367 halogens Chemical class 0.000 claims description 43
• 239000003814 drug Substances 0.000 claims description 41
• 230000002265 prevention Effects 0.000 claims description 35
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 34
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 33
• DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 33
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
• 230000005856 abnormality Effects 0.000 claims description 30
• 125000003545 alkoxy group Chemical group 0.000 claims description 29
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 27
• 229910052760 oxygen Inorganic materials 0.000 claims description 26
• 208000002193 Pain Diseases 0.000 claims description 24
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 24
• 239000008194 pharmaceutical composition Substances 0.000 claims description 24
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
• 229910052731 fluorine Inorganic materials 0.000 claims description 22
• 239000002253 acid Substances 0.000 claims description 21
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 21
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 21
• 125000004432 carbon atom Chemical group C* 0.000 claims description 20
• 229940079593 drug Drugs 0.000 claims description 20
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 20
• 230000002159 abnormal effect Effects 0.000 claims description 19
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 19
• 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 19
• 125000004104 aryloxy group Chemical group 0.000 claims description 18
• OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 18
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
• 230000036407 pain Effects 0.000 claims description 18
• 239000000126 substance Substances 0.000 claims description 18
• 125000003282 alkyl amino group Chemical group 0.000 claims description 17
• 150000001540 azides Chemical class 0.000 claims description 17
• 230000001154 acute effect Effects 0.000 claims description 16
• SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 16
• 229910052796 boron Inorganic materials 0.000 claims description 16
• 125000003107 substituted aryl group Chemical group 0.000 claims description 16
• 229910052727 yttrium Inorganic materials 0.000 claims description 16
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 15
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 15
• 238000004519 manufacturing process Methods 0.000 claims description 15
• 239000001301 oxygen Substances 0.000 claims description 15
• 206010061218 Inflammation Diseases 0.000 claims description 14
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 14
• 230000004054 inflammatory process Effects 0.000 claims description 14
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
• 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 12
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 12
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 12
• 125000000304 alkynyl group Chemical group 0.000 claims description 11
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 11
• 229910052801 chlorine Inorganic materials 0.000 claims description 11
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
• XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical class OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 claims description 11
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 11
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 10
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 10
• 125000003342 alkenyl group Chemical group 0.000 claims description 10
• 208000006673 asthma Diseases 0.000 claims description 10
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
• 125000005553 heteroaryloxy group Chemical group 0.000 claims description 10
• 230000001404 mediated effect Effects 0.000 claims description 10
• 208000010125 myocardial infarction Diseases 0.000 claims description 10
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
• 230000009529 traumatic brain injury Effects 0.000 claims description 10
• 208000020339 Spinal injury Diseases 0.000 claims description 9
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 9
• 125000004414 alkyl thio group Chemical group 0.000 claims description 9
• 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 9
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
• SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical class NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 claims description 9
• 125000004076 pyridyl group Chemical group 0.000 claims description 9
• 208000023275 Autoimmune disease Diseases 0.000 claims description 8
• 206010046851 Uveitis Diseases 0.000 claims description 8
• 206010003246 arthritis Diseases 0.000 claims description 8
• 229910052799 carbon Inorganic materials 0.000 claims description 8
• 208000004296 neuralgia Diseases 0.000 claims description 8
• 201000008482 osteoarthritis Diseases 0.000 claims description 8
• 208000023504 respiratory system disease Diseases 0.000 claims description 8
• 208000018737 Parkinson disease Diseases 0.000 claims description 7
• 230000002757 inflammatory effect Effects 0.000 claims description 7
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
• 206010028980 Neoplasm Diseases 0.000 claims description 6
• 125000003277 amino group Chemical group 0.000 claims description 6
• 229940049706 benzodiazepine Drugs 0.000 claims description 6
• 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims description 6
• 206010015037 epilepsy Diseases 0.000 claims description 6
• 150000002632 lipids Chemical class 0.000 claims description 6
• WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 6
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 6
• 125000005017 substituted alkenyl group Chemical group 0.000 claims description 6
• IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims description 5
• 208000019901 Anxiety disease Diseases 0.000 claims description 5
• 201000001320 Atherosclerosis Diseases 0.000 claims description 5
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
• 208000006561 Cluster Headache Diseases 0.000 claims description 5
• 206010019233 Headaches Diseases 0.000 claims description 5
• 206010020751 Hypersensitivity Diseases 0.000 claims description 5
• 206010065390 Inflammatory pain Diseases 0.000 claims description 5
• 208000019695 Migraine disease Diseases 0.000 claims description 5
• 208000008589 Obesity Diseases 0.000 claims description 5
• 201000004681 Psoriasis Diseases 0.000 claims description 5
• 206010043269 Tension headache Diseases 0.000 claims description 5
• 208000008548 Tension-Type Headache Diseases 0.000 claims description 5
• 230000036506 anxiety Effects 0.000 claims description 5
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 5
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 5
• 229910052794 bromium Inorganic materials 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 230000001684 chronic effect Effects 0.000 claims description 5
• 208000018912 cluster headache syndrome Diseases 0.000 claims description 5
• 208000035475 disorder Diseases 0.000 claims description 5
• 230000004064 dysfunction Effects 0.000 claims description 5
• 231100000869 headache Toxicity 0.000 claims description 5
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
• 206010027599 migraine Diseases 0.000 claims description 5
• 208000021722 neuropathic pain Diseases 0.000 claims description 5
• 235000020824 obesity Nutrition 0.000 claims description 5
• 201000000980 schizophrenia Diseases 0.000 claims description 5
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 5
• 208000004371 toothache Diseases 0.000 claims description 5
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
• 208000020925 Bipolar disease Diseases 0.000 claims description 4
• 208000034347 Faecal incontinence Diseases 0.000 claims description 4
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
• 208000003251 Pruritus Diseases 0.000 claims description 4
• 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
• 206010046543 Urinary incontinence Diseases 0.000 claims description 4
• 201000010105 allergic rhinitis Diseases 0.000 claims description 4
• 230000007815 allergy Effects 0.000 claims description 4
• UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
• 206010014599 encephalitis Diseases 0.000 claims description 4
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
• 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 claims description 4
• 230000003959 neuroinflammation Effects 0.000 claims description 4
• 230000002981 neuropathic effect Effects 0.000 claims description 4
• 210000002307 prostate Anatomy 0.000 claims description 4
• 230000000241 respiratory effect Effects 0.000 claims description 4
• 125000004426 substituted alkynyl group Chemical group 0.000 claims description 4
• RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical group SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 claims description 4
• YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 4
• 230000002485 urinary effect Effects 0.000 claims description 4
• 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 3
• 208000000094 Chronic Pain Diseases 0.000 claims description 3
• 208000030814 Eating disease Diseases 0.000 claims description 3
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
• 208000026935 allergic disease Diseases 0.000 claims description 3
• 125000005605 benzo group Chemical group 0.000 claims description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
• 235000014632 disordered eating Nutrition 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 239000012528 membrane Substances 0.000 claims description 3
• 201000006417 multiple sclerosis Diseases 0.000 claims description 3
• 150000003248 quinolines Chemical group 0.000 claims description 3
• 208000036273 reactive airway disease Diseases 0.000 claims description 3
• 208000019116 sleep disease Diseases 0.000 claims description 3
• WITJHZRCLVXYCA-UHFFFAOYSA-N 3h-1,2-benzodioxepine Chemical compound C1=CCOOC2=CC=CC=C21 WITJHZRCLVXYCA-UHFFFAOYSA-N 0.000 claims description 2
• 206010026749 Mania Diseases 0.000 claims description 2
• 239000005864 Sulphur Substances 0.000 claims description 2
• 239000007983 Tris buffer Substances 0.000 claims description 2
• 208000005298 acute pain Diseases 0.000 claims description 2
• 208000010877 cognitive disease Diseases 0.000 claims description 2
• 230000001149 cognitive effect Effects 0.000 claims description 2
• 235000005686 eating Nutrition 0.000 claims description 2
• 150000002429 hydrazines Chemical class 0.000 claims description 2
• 230000007958 sleep Effects 0.000 claims description 2
• 125000000565 sulfonamide group Chemical group 0.000 claims description 2
• BZWKPZBXAMTXNQ-UHFFFAOYSA-N sulfurocyanidic acid Chemical compound OS(=O)(=O)C#N BZWKPZBXAMTXNQ-UHFFFAOYSA-N 0.000 claims description 2
• OFFSPAZVIVZPHU-UHFFFAOYSA-N 1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC2=C1 OFFSPAZVIVZPHU-UHFFFAOYSA-N 0.000 claims 7
• 125000004149 thio group Chemical group *S* 0.000 claims 5
• LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 claims 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 4
• 125000003944 tolyl group Chemical group 0.000 claims 4
• UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 claims 3
• NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 claims 3
• JETRXAHRPACNMA-UHFFFAOYSA-N 5-chloro-1-benzofuran-2-carboxylic acid Chemical compound ClC1=CC=C2OC(C(=O)O)=CC2=C1 JETRXAHRPACNMA-UHFFFAOYSA-N 0.000 claims 2
• GUOMINFEASCICM-UHFFFAOYSA-N 5-phenylfuran-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1C1=CC=CC=C1 GUOMINFEASCICM-UHFFFAOYSA-N 0.000 claims 2
• 201000009961 allergic asthma Diseases 0.000 claims 2
• 125000000113 cyclohexyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
• 230000036737 immune function Effects 0.000 claims 2
• 230000000968 intestinal effect Effects 0.000 claims 2
• 210000003734 kidney Anatomy 0.000 claims 2
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
• QJNFJEMGWIQMJT-UHFFFAOYSA-N 1-(4-chlorophenyl)cyclopentane-1-carboxylic acid Chemical compound C=1C=C(Cl)C=CC=1C1(C(=O)O)CCCC1 QJNFJEMGWIQMJT-UHFFFAOYSA-N 0.000 claims 1
• BECYULUBGXKWFT-UHFFFAOYSA-N 2-(1-benzothiophen-3-yl)-n-[2-(2-hydroxy-2-methylpropyl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound C1=CC=C2C(CC(=O)NC3=C4C=CN(C(C4=CC=C3)=O)CC(C)(O)C)=CSC2=C1 BECYULUBGXKWFT-UHFFFAOYSA-N 0.000 claims 1
• HUKFRPZKURKTQB-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)ethanimidamide Chemical compound NC(=N)CC1=CC=C(Cl)C=C1Cl HUKFRPZKURKTQB-UHFFFAOYSA-N 0.000 claims 1
• QWOMPPPKSVQFSJ-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)-n-[2-(1-hydroxypropan-2-yl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound COC1=CC=C(OC)C(CC(=O)NC=2C3=C(C(N(C(C)CO)C=C3)=O)C=CC=2)=C1 QWOMPPPKSVQFSJ-UHFFFAOYSA-N 0.000 claims 1
• UFSZNGPKJWFSHR-CYBMUJFWSA-N 2-(4-chloro-3-fluorophenyl)-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(F)=C1 UFSZNGPKJWFSHR-CYBMUJFWSA-N 0.000 claims 1
• SEVGEQILXTWYEW-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-n-[2-(2-hydroxypropyl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound C1=CC(OCC)=CC=C1CC(=O)NC1=CC=CC2=C1C=CN(CC(C)O)C2=O SEVGEQILXTWYEW-UHFFFAOYSA-N 0.000 claims 1
• JECILOFRRYCNDH-CYBMUJFWSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 JECILOFRRYCNDH-CYBMUJFWSA-N 0.000 claims 1
• YQCWKEXWNLIHRW-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-n-[1-oxo-2-(piperidin-4-ylmethyl)isoquinolin-5-yl]acetamide Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(CC(=O)NC=2C3=C(C(N(CC4CCNCC4)C=C3)=O)C=CC=2)=C1 YQCWKEXWNLIHRW-UHFFFAOYSA-N 0.000 claims 1
• XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 claims 1
• GEOUYACEEDVFLV-UHFFFAOYSA-N 3-ethoxy-n-[2-(2-hydroxy-2-methylpropyl)-1-oxoisoquinolin-5-yl]benzamide Chemical compound CCOC1=CC=CC(C(=O)NC=2C3=C(C(N(CC(C)(C)O)C=C3)=O)C=CC=2)=C1 GEOUYACEEDVFLV-UHFFFAOYSA-N 0.000 claims 1
• XRJAXEQHLLNGBI-UHFFFAOYSA-N 4-chloro-n-[2-(2-hydroxy-2-methylpropyl)-1-oxoisoquinolin-5-yl]-2-methylbenzamide Chemical compound CC1=CC(Cl)=CC=C1C(=O)NC1=CC=CC2=C1C=CN(CC(C)(C)O)C2=O XRJAXEQHLLNGBI-UHFFFAOYSA-N 0.000 claims 1
• UQCVLWQVZLBATG-UHFFFAOYSA-N 4-chloro-n-[2-(2-hydroxypropyl)-1-oxoisoquinolin-5-yl]-2-methylbenzamide Chemical compound C1=CC=C2C(=O)N(CC(O)C)C=CC2=C1NC(=O)C1=CC=C(Cl)C=C1C UQCVLWQVZLBATG-UHFFFAOYSA-N 0.000 claims 1
• AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 claims 1
• 208000019693 Lung disease Diseases 0.000 claims 1
• XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 1
• QCVFRYSVDLJBFN-UHFFFAOYSA-N N1N=CC=CC2=C1C=CC=C2.[Bi] Chemical class N1N=CC=CC2=C1C=CC=C2.[Bi] QCVFRYSVDLJBFN-UHFFFAOYSA-N 0.000 claims 1
• 206010061876 Obstruction Diseases 0.000 claims 1
• 102000029797 Prion Human genes 0.000 claims 1
• 108091000054 Prion Proteins 0.000 claims 1
• 208000025844 Prostatic disease Diseases 0.000 claims 1
• 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
• 241000219094 Vitaceae Species 0.000 claims 1
• 208000030961 allergic reaction Diseases 0.000 claims 1
• 208000037765 diseases and disorders Diseases 0.000 claims 1
• 235000021021 grapes Nutrition 0.000 claims 1
• 125000001475 halogen functional group Chemical group 0.000 claims 1
• 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
• UERXGFNPFBCBEW-UHFFFAOYSA-N n-[2-(2-hydroxy-2-methylpropyl)-1-oxoisoquinolin-5-yl]-2-(2,4,6-trimethylphenyl)acetamide Chemical compound CC1=CC(C)=CC(C)=C1CC(=O)NC1=CC=CC2=C1C=CN(CC(C)(C)O)C2=O UERXGFNPFBCBEW-UHFFFAOYSA-N 0.000 claims 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
• 229940080818 propionamide Drugs 0.000 claims 1
• 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
• 210000000664 rectum Anatomy 0.000 claims 1
• 230000001568 sexual effect Effects 0.000 claims 1
• 230000000699 topical effect Effects 0.000 claims 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 257
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 249
• 239000000203 mixture Substances 0.000 description 127
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 126
• 238000004949 mass spectrometry Methods 0.000 description 120
• 235000019439 ethyl acetate Nutrition 0.000 description 113
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 84
• 239000002904 solvent Substances 0.000 description 83
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 82
• 238000000034 method Methods 0.000 description 81
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 69
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 65
• 230000002829 reductive effect Effects 0.000 description 65
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
• 239000007787 solid Substances 0.000 description 57
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 56
• 210000004027 cell Anatomy 0.000 description 56
• 239000011541 reaction mixture Substances 0.000 description 54
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 42
• 239000000243 solution Substances 0.000 description 42
• 238000005481 NMR spectroscopy Methods 0.000 description 37
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 37
• 239000000047 product Substances 0.000 description 37
• 150000002148 esters Chemical class 0.000 description 34
• 238000003818 flash chromatography Methods 0.000 description 34
• 239000004202 carbamide Substances 0.000 description 33
• 235000013877 carbamide Nutrition 0.000 description 33
• 241001465754 Metazoa Species 0.000 description 32
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 31
• 150000002431 hydrogen Chemical class 0.000 description 29
• 238000012360 testing method Methods 0.000 description 29
• 150000003254 radicals Chemical class 0.000 description 28
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 27
• 102000005962 receptors Human genes 0.000 description 27
• 108020003175 receptors Proteins 0.000 description 27
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
• 241000700159 Rattus Species 0.000 description 25
• 206010057190 Respiratory tract infections Diseases 0.000 description 24
• 239000000460 chlorine Substances 0.000 description 24
• 239000003921 oil Substances 0.000 description 22
• 235000019198 oils Nutrition 0.000 description 22
• 125000005309 thioalkoxy group Chemical class 0.000 description 22
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 20
• 230000000694 effects Effects 0.000 description 19
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 18
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
• 239000002585 base Substances 0.000 description 18
• 229910052938 sodium sulfate Inorganic materials 0.000 description 18
• 235000011152 sodium sulphate Nutrition 0.000 description 18
• 239000003039 volatile agent Substances 0.000 description 18
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 17
• 239000012267 brine Substances 0.000 description 17
• 239000012044 organic layer Substances 0.000 description 17
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
• 229910052757 nitrogen Inorganic materials 0.000 description 16
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
• 239000000741 silica gel Substances 0.000 description 16
• 229910002027 silica gel Inorganic materials 0.000 description 16
• 238000005160 1H NMR spectroscopy Methods 0.000 description 15
• 239000000706 filtrate Substances 0.000 description 15
• 229910052763 palladium Inorganic materials 0.000 description 15
• 238000003756 stirring Methods 0.000 description 15
• 229910052721 tungsten Inorganic materials 0.000 description 15
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 14
• 210000004369 blood Anatomy 0.000 description 14
• 239000008280 blood Substances 0.000 description 14
• 238000002474 experimental method Methods 0.000 description 14
• 238000009472 formulation Methods 0.000 description 14
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 14
• 238000002953 preparative HPLC Methods 0.000 description 14
• 239000000651 prodrug Substances 0.000 description 14
• 229940002612 prodrug Drugs 0.000 description 14
• 239000012265 solid product Substances 0.000 description 14
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 14
• 241000124008 Mammalia Species 0.000 description 13
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
• 239000000546 pharmaceutical excipient Substances 0.000 description 13
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 13
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
• 230000015572 biosynthetic process Effects 0.000 description 12
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 239000010410 layer Substances 0.000 description 12
• 210000002540 macrophage Anatomy 0.000 description 12
• 239000007858 starting material Substances 0.000 description 12
• 125000005415 substituted alkoxy group Chemical group 0.000 description 12
• 125000005346 substituted cycloalkyl group Chemical class 0.000 description 12
• 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 description 11
• 230000002441 reversible effect Effects 0.000 description 11
• 125000005296 thioaryloxy group Chemical group 0.000 description 11
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 10
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
• 125000004429 atom Chemical group 0.000 description 10
• 229910052740 iodine Inorganic materials 0.000 description 10
• 229910052742 iron Inorganic materials 0.000 description 10
• 239000011734 sodium Substances 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
• QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 9
• 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 9
• 235000019270 ammonium chloride Nutrition 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 210000000269 carotid artery external Anatomy 0.000 description 9
• 210000001072 colon Anatomy 0.000 description 9
• 125000005842 heteroatom Chemical group 0.000 description 9
• 230000000155 isotopic effect Effects 0.000 description 9
• 239000002244 precipitate Substances 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
• 238000010992 reflux Methods 0.000 description 9
• 229910052717 sulfur Inorganic materials 0.000 description 9
• OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 8
• AZBFOENSKLAYKT-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(C(F)(F)F)=C1 AZBFOENSKLAYKT-UHFFFAOYSA-N 0.000 description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• 241000282412 Homo Species 0.000 description 8
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
• 239000000556 agonist Substances 0.000 description 8
• 125000000392 cycloalkenyl group Chemical group 0.000 description 8
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 8
• 125000000468 ketone group Chemical class 0.000 description 8
• 210000002433 mononuclear leukocyte Anatomy 0.000 description 8
• 229910000027 potassium carbonate Inorganic materials 0.000 description 8
• 229920006395 saturated elastomer Polymers 0.000 description 8
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
• AWJJLYZBWRIBCZ-UGTJMOTHSA-N 3'-O-(4-Benzoyl)benzoyl ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 AWJJLYZBWRIBCZ-UGTJMOTHSA-N 0.000 description 7
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
• 229930194542 Keto Chemical class 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 7
• 125000002619 bicyclic group Chemical group 0.000 description 7
• 239000001110 calcium chloride Substances 0.000 description 7
• 229910001628 calcium chloride Inorganic materials 0.000 description 7
• 235000011148 calcium chloride Nutrition 0.000 description 7
• 239000003054 catalyst Substances 0.000 description 7
• 238000004440 column chromatography Methods 0.000 description 7
• 239000002158 endotoxin Substances 0.000 description 7
• 239000000284 extract Substances 0.000 description 7
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 7
• 229920006008 lipopolysaccharide Polymers 0.000 description 7
• 210000005036 nerve Anatomy 0.000 description 7
• 208000015122 neurodegenerative disease Diseases 0.000 description 7
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
• 229920000053 polysorbate 80 Polymers 0.000 description 7
• 239000012453 solvate Substances 0.000 description 7
• 229960005322 streptomycin Drugs 0.000 description 7
• 208000011580 syndromic disease Diseases 0.000 description 7
• 238000005303 weighing Methods 0.000 description 7
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
• 239000012981 Hank's balanced salt solution Substances 0.000 description 6
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
• 229930182555 Penicillin Natural products 0.000 description 6
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
• 239000012980 RPMI-1640 medium Substances 0.000 description 6
• 241000206572 Rhodophyta Species 0.000 description 6
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
• 150000008064 anhydrides Chemical class 0.000 description 6
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 6
• 229960005542 ethidium bromide Drugs 0.000 description 6
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
• 125000000524 functional group Chemical group 0.000 description 6
• 125000000623 heterocyclic group Chemical group 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 208000026278 immune system disease Diseases 0.000 description 6
• 239000013067 intermediate product Substances 0.000 description 6
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 230000004770 neurodegeneration Effects 0.000 description 6
• 229940049954 penicillin Drugs 0.000 description 6
• 239000000843 powder Substances 0.000 description 6
• 235000019260 propionic acid Nutrition 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• YOZILQVNIWNPFP-LURJTMIESA-N (2s)-2-(4-chlorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=C(Cl)C=C1 YOZILQVNIWNPFP-LURJTMIESA-N 0.000 description 5
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
• ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 5
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 5
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 150000001335 aliphatic alkanes Chemical class 0.000 description 5
• 150000001721 carbon Chemical group 0.000 description 5
• SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 5
• 150000001768 cations Chemical class 0.000 description 5
• 238000005119 centrifugation Methods 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 5
• 238000004821 distillation Methods 0.000 description 5
• 201000002491 encephalomyelitis Diseases 0.000 description 5
• 235000013305 food Nutrition 0.000 description 5
• 239000011521 glass Substances 0.000 description 5
• 125000005843 halogen group Chemical group 0.000 description 5
• 150000002430 hydrocarbons Chemical group 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 239000007937 lozenge Substances 0.000 description 5
• 208000033808 peripheral neuropathy Diseases 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 150000004032 porphyrins Chemical class 0.000 description 5
• 239000011591 potassium Substances 0.000 description 5
• 229910052700 potassium Inorganic materials 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
• SEQXIBXVFUCLJI-SSDOTTSWSA-N (2r)-2-(5-nitro-1-oxoisoquinolin-2-yl)propanamide Chemical compound C1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1[N+]([O-])=O SEQXIBXVFUCLJI-SSDOTTSWSA-N 0.000 description 4
• FIAINKIUSZGVGX-HSHFZTNMSA-N (2r)-2-aminopropanamide;hydrochloride Chemical compound Cl.C[C@@H](N)C(N)=O FIAINKIUSZGVGX-HSHFZTNMSA-N 0.000 description 4
• LRBGMTZLMIMKLP-UHFFFAOYSA-N 4-chloro-2-methyl-3-nitrobenzoic acid Chemical compound CC1=C(C(O)=O)C=CC(Cl)=C1[N+]([O-])=O LRBGMTZLMIMKLP-UHFFFAOYSA-N 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
• 102100037602 P2X purinoceptor 7 Human genes 0.000 description 4
• 101710189965 P2X purinoceptor 7 Proteins 0.000 description 4
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 125000002252 acyl group Chemical group 0.000 description 4
• 125000001931 aliphatic group Chemical group 0.000 description 4
• 125000005907 alkyl ester group Chemical group 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 150000001454 anthracenes Chemical class 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
• 230000002526 effect on cardiovascular system Effects 0.000 description 4
• 210000002683 foot Anatomy 0.000 description 4
• 239000008103 glucose Substances 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 150000002500 ions Chemical class 0.000 description 4
• 229960002725 isoflurane Drugs 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000011777 magnesium Substances 0.000 description 4
• 229910052749 magnesium Inorganic materials 0.000 description 4
• OBEIQHRWPFVXDA-UHFFFAOYSA-N methyl 4-chloro-2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1C OBEIQHRWPFVXDA-UHFFFAOYSA-N 0.000 description 4
• 210000003205 muscle Anatomy 0.000 description 4
• 201000001119 neuropathy Diseases 0.000 description 4
• 230000007823 neuropathy Effects 0.000 description 4
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
• 125000005323 thioketone group Chemical group 0.000 description 4
• CWLQUGTUXBXTLF-RXMQYKEDSA-N (2r)-1-methylpyrrolidine-2-carboxylic acid Chemical compound CN1CCC[C@@H]1C(O)=O CWLQUGTUXBXTLF-RXMQYKEDSA-N 0.000 description 3
• FMMHWBBVJVYYBG-OAHLLOKOSA-N (2r)-2-(5-nitro-1-oxoisoquinolin-2-yl)-2-phenylacetamide Chemical compound C1([C@H](C(=O)N)N2C(C3=CC=CC(=C3C=C2)[N+]([O-])=O)=O)=CC=CC=C1 FMMHWBBVJVYYBG-OAHLLOKOSA-N 0.000 description 3
• SEQXIBXVFUCLJI-ZETCQYMHSA-N (2s)-2-(5-nitro-1-oxoisoquinolin-2-yl)propanamide Chemical compound C1=CC=C2C(=O)N([C@H](C(N)=O)C)C=CC2=C1[N+]([O-])=O SEQXIBXVFUCLJI-ZETCQYMHSA-N 0.000 description 3
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
• ZFOWDXKJQNNLMW-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 ZFOWDXKJQNNLMW-UHFFFAOYSA-N 0.000 description 3
• HNORVZDAANCHAY-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(C(F)(F)F)C=C1 HNORVZDAANCHAY-UHFFFAOYSA-N 0.000 description 3
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 3
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
• 108091006146 Channels Proteins 0.000 description 3
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 239000005977 Ethylene Substances 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 208000004454 Hyperalgesia Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 102100037850 Interferon gamma Human genes 0.000 description 3
• 108010074328 Interferon-gamma Proteins 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
• 206010030124 Oedema peripheral Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 150000001336 alkenes Chemical group 0.000 description 3
• 150000001345 alkine derivatives Chemical class 0.000 description 3
• 125000002947 alkylene group Chemical group 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
• 210000001367 artery Anatomy 0.000 description 3
• 125000001769 aryl amino group Chemical group 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 239000007853 buffer solution Substances 0.000 description 3
• 210000001715 carotid artery Anatomy 0.000 description 3
• 210000004004 carotid artery internal Anatomy 0.000 description 3
• 239000003610 charcoal Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000009089 cytolysis Effects 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 125000006612 decyloxy group Chemical group 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 239000007789 gas Substances 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 150000004677 hydrates Chemical class 0.000 description 3
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
• 235000019341 magnesium sulphate Nutrition 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
• 210000003657 middle cerebral artery Anatomy 0.000 description 3
• 125000001624 naphthyl group Chemical group 0.000 description 3
• 230000000926 neurological effect Effects 0.000 description 3
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
• 150000002923 oximes Chemical class 0.000 description 3
• 230000035515 penetration Effects 0.000 description 3
• 230000008823 permeabilization Effects 0.000 description 3
• 239000011148 porous material Substances 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 239000000018 receptor agonist Substances 0.000 description 3
• 229940044601 receptor agonist Drugs 0.000 description 3
• 210000003497 sciatic nerve Anatomy 0.000 description 3
• DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 238000003797 solvolysis reaction Methods 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 150000003505 terpenes Chemical class 0.000 description 3
• 235000007586 terpenes Nutrition 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 229930192474 thiophene Natural products 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• YOZILQVNIWNPFP-ZCFIWIBFSA-N (2r)-2-(4-chlorophenyl)propanoic acid Chemical compound OC(=O)[C@H](C)C1=CC=C(Cl)C=C1 YOZILQVNIWNPFP-ZCFIWIBFSA-N 0.000 description 2
• KCXHNMLLTDDETF-OAHLLOKOSA-N (2r)-2-(5-amino-1-oxoisoquinolin-2-yl)-2-phenylacetamide Chemical compound C1([C@H](C(=O)N)N2C(C3=CC=CC(N)=C3C=C2)=O)=CC=CC=C1 KCXHNMLLTDDETF-OAHLLOKOSA-N 0.000 description 2
• WNUCRXXBFRWADY-ZCFIWIBFSA-N (2r)-2-(6-chloro-5-nitro-1-oxoisoquinolin-2-yl)propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1[N+]([O-])=O WNUCRXXBFRWADY-ZCFIWIBFSA-N 0.000 description 2
• CBDITEXCLUWSGA-GFCCVEGCSA-N (2r)-3-methyl-2-(5-nitro-1-oxoisoquinolin-2-yl)butanoic acid Chemical compound C1=CC=C2C(=O)N([C@@H](C(O)=O)C(C)C)C=CC2=C1[N+]([O-])=O CBDITEXCLUWSGA-GFCCVEGCSA-N 0.000 description 2
• WNUCRXXBFRWADY-LURJTMIESA-N (2s)-2-(6-chloro-5-nitro-1-oxoisoquinolin-2-yl)propanamide Chemical compound ClC1=CC=C2C(=O)N([C@H](C(N)=O)C)C=CC2=C1[N+]([O-])=O WNUCRXXBFRWADY-LURJTMIESA-N 0.000 description 2
• HTCXXFDQLVLURJ-JTQLQIEISA-N (2s)-3-hydroxy-2-(5-nitro-1-oxoisoquinolin-2-yl)propanamide Chemical compound C1=CC=C2C(=O)N([C@@H](CO)C(=O)N)C=CC2=C1[N+]([O-])=O HTCXXFDQLVLURJ-JTQLQIEISA-N 0.000 description 2
• UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
• GWGBNENHEGYJSN-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GWGBNENHEGYJSN-UHFFFAOYSA-N 0.000 description 2
• QSRJROVBSIIPKY-UHFFFAOYSA-N 2-(1,3-dihydroxypropan-2-yl)-5-nitroisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N(C(CO)CO)C=CC2=C1[N+]([O-])=O QSRJROVBSIIPKY-UHFFFAOYSA-N 0.000 description 2
• XRTYQXOYMPQKPL-UHFFFAOYSA-N 2-(2-hydroxyethyl)-5-nitroisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N(CCO)C=CC2=C1[N+]([O-])=O XRTYQXOYMPQKPL-UHFFFAOYSA-N 0.000 description 2
• FBGJNTRPCQKHNJ-UHFFFAOYSA-N 2-(5-amino-1-oxoisoquinolin-2-yl)-2-(4-chlorophenyl)acetamide Chemical compound C1=CC2=C(N)C=CC=C2C(=O)N1C(C(=O)N)C1=CC=C(Cl)C=C1 FBGJNTRPCQKHNJ-UHFFFAOYSA-N 0.000 description 2
• MCUFIQRDDIFSIJ-UHFFFAOYSA-N 2-(5-nitro-1-oxoisoquinolin-2-yl)acetamide Chemical compound C1=CC=C2C(=O)N(CC(=O)N)C=CC2=C1[N+]([O-])=O MCUFIQRDDIFSIJ-UHFFFAOYSA-N 0.000 description 2
• LMPORRRHHAJHIG-SECBINFHSA-N 2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-5-nitroisoquinolin-1-one Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1[N+]([O-])=O LMPORRRHHAJHIG-SECBINFHSA-N 0.000 description 2
• UKSTVTZXWKFMHX-UHFFFAOYSA-N 2-[4-chloro-2-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1C(F)(F)F UKSTVTZXWKFMHX-UHFFFAOYSA-N 0.000 description 2
• MGQPQAYFSXCYPW-UHFFFAOYSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 MGQPQAYFSXCYPW-UHFFFAOYSA-N 0.000 description 2
• UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• XXFKOBGFMUIWDH-UHFFFAOYSA-M 4-chloro-2-methylbenzoate Chemical compound CC1=CC(Cl)=CC=C1C([O-])=O XXFKOBGFMUIWDH-UHFFFAOYSA-M 0.000 description 2
• FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 2
• WAVJTIBLOFDVEO-UHFFFAOYSA-N 6-chloro-2-(2-hydroxyethyl)-5-nitroisoquinolin-1-one Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1[N+]([O-])=O WAVJTIBLOFDVEO-UHFFFAOYSA-N 0.000 description 2
• SJAVUAZUMAXZHV-SSDOTTSWSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-5-nitroisoquinolin-1-one Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1[N+]([O-])=O SJAVUAZUMAXZHV-SSDOTTSWSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 241000588832 Bordetella pertussis Species 0.000 description 2
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 206010057248 Cell death Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 2
• 102000000503 Collagen Type II Human genes 0.000 description 2
• 108010041390 Collagen Type II Proteins 0.000 description 2
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
• 235000004035 Cryptotaenia japonica Nutrition 0.000 description 2
• 244000146493 Cryptotaenia japonica Species 0.000 description 2
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• ZERULLAPCVRMCO-UHFFFAOYSA-N Dipropyl sulfide Chemical compound CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 2
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
• 208000009386 Experimental Arthritis Diseases 0.000 description 2
• 208000001640 Fibromyalgia Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 208000035154 Hyperesthesia Diseases 0.000 description 2
• 206010061216 Infarction Diseases 0.000 description 2
• 208000008081 Intestinal Fistula Diseases 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
• LOFNIQFZLFOTNY-ZDUSSCGKSA-N NC1=C2C=CN(C(C2=CC=C1)=O)[C@@H](CN)C(C)C Chemical compound NC1=C2C=CN(C(C2=CC=C1)=O)[C@@H](CN)C(C)C LOFNIQFZLFOTNY-ZDUSSCGKSA-N 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 206010033645 Pancreatitis Diseases 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• 108010081690 Pertussis Toxin Proteins 0.000 description 2
• 208000004983 Phantom Limb Diseases 0.000 description 2
• 206010056238 Phantom pain Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
• 102000002294 Purinergic P2X Receptors Human genes 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
• 208000012931 Urologic disease Diseases 0.000 description 2
• PTKRUDMLGIIORX-ITGWJZMWSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate;cyclohexanamine Chemical compound NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 PTKRUDMLGIIORX-ITGWJZMWSA-N 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 229960001456 adenosine triphosphate Drugs 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000000730 antalgic agent Substances 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 235000014121 butter Nutrition 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 210000001168 carotid artery common Anatomy 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 229960001231 choline Drugs 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000000000 cycloalkoxy group Chemical group 0.000 description 2
• 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 2
• JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 150000005690 diesters Chemical group 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 210000000548 hind-foot Anatomy 0.000 description 2
• 230000000642 iatrogenic effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000007574 infarction Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 230000001057 ionotropic effect Effects 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 210000002414 leg Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
• HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
• 229910001629 magnesium chloride Inorganic materials 0.000 description 2
• 229910001425 magnesium ion Inorganic materials 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 239000011976 maleic acid Substances 0.000 description 2
• JBXLGRYXUPBUFC-BQYQJAHWSA-N methyl 2-[(e)-2-(dimethylamino)ethenyl]-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1\C=C\N(C)C JBXLGRYXUPBUFC-BQYQJAHWSA-N 0.000 description 2
• CRZGFIMLHZTLGT-UHFFFAOYSA-N methyl 2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1C CRZGFIMLHZTLGT-UHFFFAOYSA-N 0.000 description 2
• 229940050176 methyl chloride Drugs 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 239000003068 molecular probe Substances 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 2
• DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
• GGEJMOOCDLBKMG-UHFFFAOYSA-N n-[2-(5-nitro-1-oxoisoquinolin-2-yl)ethyl]acetamide Chemical compound C1=CC=C2C(=O)N(CCNC(=O)C)C=CC2=C1[N+]([O-])=O GGEJMOOCDLBKMG-UHFFFAOYSA-N 0.000 description 2
• 230000000626 neurodegenerative effect Effects 0.000 description 2
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
• 229910017604 nitric acid Inorganic materials 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
• RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
• ZORAAXQLJQXLOD-UHFFFAOYSA-N phosphonamidous acid Chemical group NPO ZORAAXQLJQXLOD-UHFFFAOYSA-N 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 229920000728 polyester Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 238000012877 positron emission topography Methods 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 239000001294 propane Substances 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 239000012264 purified product Substances 0.000 description 2
• 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
• 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
• NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 2
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 239000000376 reactant Substances 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000011514 reflex Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 235000008790 seltzer Nutrition 0.000 description 2
• 230000001953 sensory effect Effects 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 229910001220 stainless steel Inorganic materials 0.000 description 2
• 239000010935 stainless steel Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
• 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 239000011975 tartaric acid Substances 0.000 description 2
• 235000002906 tartaric acid Nutrition 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 206010044652 trigeminal neuralgia Diseases 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 210000001364 upper extremity Anatomy 0.000 description 2
• 208000014001 urinary system disease Diseases 0.000 description 2
• 208000009935 visceral pain Diseases 0.000 description 2
• AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
• WYRSGXAIHNMKOL-UHFFFAOYSA-N $l^{1}-sulfanylethane Chemical compound CC[S] WYRSGXAIHNMKOL-UHFFFAOYSA-N 0.000 description 1
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• NSOVNUROTILTJA-SECBINFHSA-N (2r)-2-(5-amino-1-oxoisoquinolin-2-yl)-n-cyclopropylpropanamide Chemical compound O=C([C@@H](C)N1C(C2=CC=CC(N)=C2C=C1)=O)NC1CC1 NSOVNUROTILTJA-SECBINFHSA-N 0.000 description 1
• GITOYMUZGBNOSS-ZCFIWIBFSA-N (2r)-2-(5-amino-6-chloro-1-oxoisoquinolin-2-yl)propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1N GITOYMUZGBNOSS-ZCFIWIBFSA-N 0.000 description 1
• FKHLQYYXBMOWNR-SSDOTTSWSA-N (2r)-2-(5-nitro-1-oxoisoquinolin-2-yl)propanoic acid Chemical compound C1=CC=C2C(=O)N([C@@H](C(O)=O)C)C=CC2=C1[N+]([O-])=O FKHLQYYXBMOWNR-SSDOTTSWSA-N 0.000 description 1
• GDFAOVXKHJXLEI-GSVOUGTGSA-N (2r)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C)C(O)=O GDFAOVXKHJXLEI-GSVOUGTGSA-N 0.000 description 1
• VPSSPAXIFBTOHY-ZCFIWIBFSA-N (2r)-2-amino-4-methylpentan-1-ol Chemical compound CC(C)C[C@@H](N)CO VPSSPAXIFBTOHY-ZCFIWIBFSA-N 0.000 description 1
• VVRVZXIIKFLHIH-NRYLJRBGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO.C[C@@H](N)CO VVRVZXIIKFLHIH-NRYLJRBGSA-N 0.000 description 1
• SKJADVKDCNFCIR-SECBINFHSA-N (2r)-n-cyclopropyl-2-(5-nitro-1-oxoisoquinolin-2-yl)propanamide Chemical compound O=C([C@@H](C)N1C(C2=CC=CC(=C2C=C1)[N+]([O-])=O)=O)NC1CC1 SKJADVKDCNFCIR-SECBINFHSA-N 0.000 description 1
• JSAPFNPRLYFXQD-YFKPBYRVSA-N (2s)-2-(3,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=C(Cl)C(Cl)=C1 JSAPFNPRLYFXQD-YFKPBYRVSA-N 0.000 description 1
• VOOWAIHRFPFBAW-JTQLQIEISA-N (2s)-2-(5-amino-1-oxoisoquinolin-2-yl)-3-hydroxypropanamide Chemical compound C1=CC=C2C(=O)N([C@@H](CO)C(=O)N)C=CC2=C1N VOOWAIHRFPFBAW-JTQLQIEISA-N 0.000 description 1
• UYXRNQYXMROBRC-ZETCQYMHSA-N (2s)-2-(5-amino-1-oxoisoquinolin-2-yl)propanamide Chemical compound C1=CC=C2C(=O)N([C@H](C(N)=O)C)C=CC2=C1N UYXRNQYXMROBRC-ZETCQYMHSA-N 0.000 description 1
• GITOYMUZGBNOSS-LURJTMIESA-N (2s)-2-(5-amino-6-chloro-1-oxoisoquinolin-2-yl)propanamide Chemical compound ClC1=CC=C2C(=O)N([C@H](C(N)=O)C)C=CC2=C1N GITOYMUZGBNOSS-LURJTMIESA-N 0.000 description 1
• VIFCIENBDYQQDX-NSHDSACASA-N (2s)-2-[6-chloro-1-oxo-5-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]isoquinolin-2-yl]propanamide Chemical compound ClC1=CC=C2C(=O)N([C@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 VIFCIENBDYQQDX-NSHDSACASA-N 0.000 description 1
• MGOGKPMIZGEGOZ-REOHCLBHSA-N (2s)-2-amino-3-hydroxypropanamide Chemical compound OC[C@H](N)C(N)=O MGOGKPMIZGEGOZ-REOHCLBHSA-N 0.000 description 1
• UXUFTKZYJYGMGO-CMCWBKRRSA-N (2s,3s,4r,5r)-5-[6-amino-2-[2-[4-[3-(2-aminoethylamino)-3-oxopropyl]phenyl]ethylamino]purin-9-yl]-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(=O)NCCN)=CC=3)=NC(N)=C2N=C1 UXUFTKZYJYGMGO-CMCWBKRRSA-N 0.000 description 1
• KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
• OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• AVGQTJUPLKNPQP-UHFFFAOYSA-N 1,1,1-trichloropropane Chemical compound CCC(Cl)(Cl)Cl AVGQTJUPLKNPQP-UHFFFAOYSA-N 0.000 description 1
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
• YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
• BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
• 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
• IGGDKDTUCAWDAN-UHFFFAOYSA-N 1-vinylnaphthalene Chemical compound C1=CC=C2C(C=C)=CC=CC2=C1 IGGDKDTUCAWDAN-UHFFFAOYSA-N 0.000 description 1
• WWCXOWZYHIRUGW-UHFFFAOYSA-N 11,11-dibutyl-2-methylpentadecane Chemical compound C(CCC)C(CCCCCCCCC(C)C)(CCCC)CCCC WWCXOWZYHIRUGW-UHFFFAOYSA-N 0.000 description 1
• ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
• NGLXYIKMPIMIJB-UHFFFAOYSA-N 2-(2-hydroxyethyl)-6-(2-hydroxyethylamino)-5-nitroisoquinolin-1-one Chemical compound C1=CN(CCO)C(=O)C=2C1=C([N+]([O-])=O)C(NCCO)=CC=2 NGLXYIKMPIMIJB-UHFFFAOYSA-N 0.000 description 1
• ZOUPGSMSNQLUNW-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(Cl)=C1 ZOUPGSMSNQLUNW-UHFFFAOYSA-N 0.000 description 1
• JSAPFNPRLYFXQD-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(Cl)C(Cl)=C1 JSAPFNPRLYFXQD-UHFFFAOYSA-N 0.000 description 1
• QIYNMJFDEWFEKJ-UHFFFAOYSA-N 2-(4-chloro-3-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(F)=C1 QIYNMJFDEWFEKJ-UHFFFAOYSA-N 0.000 description 1
• UQJFNDVHQGJJQV-UHFFFAOYSA-N 2-(5-amino-1-oxoisoquinolin-2-yl)acetamide Chemical compound C1=CC=C2C(=O)N(CC(=O)N)C=CC2=C1N UQJFNDVHQGJJQV-UHFFFAOYSA-N 0.000 description 1
• OHIQYYCSGWMUHG-UHFFFAOYSA-N 2-(5-nitro-1-oxoisoquinolin-2-yl)ethyl acetate Chemical compound C1=CC=C2C(=O)N(CCOC(=O)C)C=CC2=C1[N+]([O-])=O OHIQYYCSGWMUHG-UHFFFAOYSA-N 0.000 description 1
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
• MDFXJBQEWLCGHP-MFOYZWKCSA-N 2-[2-[(z)-(pyridine-4-carbonylhydrazinylidene)methyl]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC=C1\C=N/NC(=O)C1=CC=NC=C1 MDFXJBQEWLCGHP-MFOYZWKCSA-N 0.000 description 1
• IZXLNEHPKQVCAE-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1F IZXLNEHPKQVCAE-UHFFFAOYSA-N 0.000 description 1
• HGCBZJDOYPMNEY-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-n-[2-(2-hydroxyethyl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound C1=CC=C2C(=O)N(CCO)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(C(F)(F)F)=C1 HGCBZJDOYPMNEY-UHFFFAOYSA-N 0.000 description 1
• SAJVLJRQTCZEQD-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(Cl)C(C(F)(F)F)=C1 SAJVLJRQTCZEQD-UHFFFAOYSA-N 0.000 description 1
• FXVWYAXIWINTHT-UHFFFAOYSA-N 2-[[2-(2-acetyloxyethyl)-5-amino-1-oxoisoquinolin-6-yl]amino]ethyl acetate Chemical compound C1=CN(CCOC(C)=O)C(=O)C=2C1=C(N)C(NCCOC(=O)C)=CC=2 FXVWYAXIWINTHT-UHFFFAOYSA-N 0.000 description 1
• VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
• IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
• KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
• UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
• BVRDQVRQVGRNHG-UHFFFAOYSA-N 2-morpholin-4-ylpyrimido[2,1-a]isoquinolin-4-one Chemical compound N1=C2C3=CC=CC=C3C=CN2C(=O)C=C1N1CCOCC1 BVRDQVRQVGRNHG-UHFFFAOYSA-N 0.000 description 1
• JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 1
• SKMKJBYBPYBDMN-RYUDHWBXSA-N 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine Chemical compound C1=C(OC(F)F)C(N)=NC=C1C1=CC(N2[C@H]3C[C@H](OC3)C2)=NC(N2CC(F)(F)CC2)=N1 SKMKJBYBPYBDMN-RYUDHWBXSA-N 0.000 description 1
• AFPHTEQTJZKQAQ-UHFFFAOYSA-M 3-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-M 0.000 description 1
• HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
• RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
• GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
• RMAHHKVBDRSXPT-UHFFFAOYSA-N 5-amino-2-(1,3-dihydroxypropan-2-yl)isoquinolin-1-one Chemical compound C1=CN(C(CO)CO)C(=O)C2=C1C(N)=CC=C2 RMAHHKVBDRSXPT-UHFFFAOYSA-N 0.000 description 1
• NVKJOXRVEKMMHS-UHFFFAOYSA-N 5-nitro-1,2,4-triazol-3-one Chemical compound [O-][N+](=O)C1=NC(=O)N=N1 NVKJOXRVEKMMHS-UHFFFAOYSA-N 0.000 description 1
• KAOGLTJJFLERPG-SECBINFHSA-N 6-cyclopropyl-2-[(2r)-1-hydroxypropan-2-yl]-5-nitroisoquinolin-1-one Chemical compound C=1C=C2C(=O)N([C@@H](CO)C)C=CC2=C([N+]([O-])=O)C=1C1CC1 KAOGLTJJFLERPG-SECBINFHSA-N 0.000 description 1
• LSBDFXRDZJMBSC-UHFFFAOYSA-N Amide-Phenylacetic acid Natural products NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 241000937413 Axia Species 0.000 description 1
• 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• HOYHHXGCYGFPGV-UHFFFAOYSA-N CCCCC(CCCC)(CCCC)CCCCCCCCC(C)C.Cl Chemical compound CCCCC(CCCC)(CCCC)CCCCCCCCC(C)C.Cl HOYHHXGCYGFPGV-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 101150065749 Churc1 gene Proteins 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 235000005976 Citrus sinensis Nutrition 0.000 description 1
• 240000002319 Citrus sinensis Species 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• HTIRHQRTDBPHNZ-UHFFFAOYSA-N Dibutyl sulfide Chemical compound CCCCSCCCC HTIRHQRTDBPHNZ-UHFFFAOYSA-N 0.000 description 1
• QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
• 206010061819 Disease recurrence Diseases 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
• 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
• 239000005909 Kieselgur Substances 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• 206010023799 Large intestinal ulcer Diseases 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 235000006679 Mentha X verticillata Nutrition 0.000 description 1
• 235000002899 Mentha suaveolens Nutrition 0.000 description 1
• 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
• 206010027926 Monoplegia Diseases 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• UNQGEUROCUMFLA-UHFFFAOYSA-N N,N,3-trimethyl-1H-indol-2-amine Chemical compound CN(C=1NC2=CC=CC=C2C=1C)C UNQGEUROCUMFLA-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 241001274216 Naso Species 0.000 description 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
• 239000006057 Non-nutritive feed additive Substances 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 235000019502 Orange oil Nutrition 0.000 description 1
• 102000016979 Other receptors Human genes 0.000 description 1
• 108091075598 P2X receptor family Proteins 0.000 description 1
• 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102100038239 Protein Churchill Human genes 0.000 description 1
• 108010000836 Purinergic P2X Receptors Proteins 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 206010042434 Sudden death Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• FIAINKIUSZGVGX-DKWTVANSSA-N [(2s)-1-amino-1-oxopropan-2-yl]azanium;chloride Chemical compound Cl.C[C@H](N)C(N)=O FIAINKIUSZGVGX-DKWTVANSSA-N 0.000 description 1
• QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 1
• BSCCQYSVBUPEHK-UHFFFAOYSA-N [S].ClSCl Chemical compound [S].ClSCl BSCCQYSVBUPEHK-UHFFFAOYSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 210000003489 abdominal muscle Anatomy 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
• 125000002355 alkine group Chemical group 0.000 description 1
• 125000000033 alkoxyamino group Chemical group 0.000 description 1
• 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 206010053552 allodynia Diseases 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
• CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
• 150000004056 anthraquinones Chemical class 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000002421 anti-septic effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• BVUSIQTYUVWOSX-UHFFFAOYSA-N arsindole Chemical compound C1=CC=C2[As]C=CC2=C1 BVUSIQTYUVWOSX-UHFFFAOYSA-N 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• MMRRVPNHMBMKBF-UHFFFAOYSA-N benzoic acid;bismuth Chemical class [Bi].OC(=O)C1=CC=CC=C1 MMRRVPNHMBMKBF-UHFFFAOYSA-N 0.000 description 1
• 239000012965 benzophenone Substances 0.000 description 1
• 150000008366 benzophenones Chemical class 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000003461 brachial plexus Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 125000004112 carboxyamino group Chemical group [H]OC(=O)N([H])[*] 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 230000003130 cardiopathic effect Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 229910000420 cerium oxide Inorganic materials 0.000 description 1
• SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 238000005660 chlorination reaction Methods 0.000 description 1
• HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
• QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000010779 crude oil Substances 0.000 description 1
• HZXXSCOUSGLRRX-UHFFFAOYSA-N cyanoboronic acid Chemical compound OB(O)C#N HZXXSCOUSGLRRX-UHFFFAOYSA-N 0.000 description 1
• 150000001924 cycloalkanes Chemical class 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 150000001934 cyclohexanes Chemical group 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000009849 deactivation Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
• YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 229940052761 dopaminergic adamantane derivative Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 238000002001 electrophysiology Methods 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 150000002085 enols Chemical class 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
• 229960003750 ethyl chloride Drugs 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 210000003099 femoral nerve Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 229960001269 glycine hydrochloride Drugs 0.000 description 1
• 230000021061 grooming behavior Effects 0.000 description 1
• 125000005241 heteroarylamino group Chemical group 0.000 description 1
• 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
• PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 1
• 208000010726 hind limb paralysis Diseases 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 102000055647 human CSF2RB Human genes 0.000 description 1
• 239000008309 hydrophilic cream Substances 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 150000002467 indacenes Chemical class 0.000 description 1
• UTWGRMYWDUMKNY-UHFFFAOYSA-N indole-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)C=CC2=C1 UTWGRMYWDUMKNY-UHFFFAOYSA-N 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000012739 integrated shape imaging system Methods 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 230000003871 intestinal function Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 210000004731 jugular vein Anatomy 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 230000005830 kidney abnormality Effects 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• LTRVAZKHJRYLRJ-UHFFFAOYSA-N lithium;butan-1-olate Chemical compound [Li+].CCCC[O-] LTRVAZKHJRYLRJ-UHFFFAOYSA-N 0.000 description 1
• 210000001853 liver microsome Anatomy 0.000 description 1
• 238000011670 long-evans rat Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 210000001595 mastoid Anatomy 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037323 metabolic rate Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229940087646 methanolamine Drugs 0.000 description 1
• SFOUMZZLBCFDEN-UHFFFAOYSA-N methyl 4-bromo-2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(Br)C([N+]([O-])=O)=C1C SFOUMZZLBCFDEN-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 150000002790 naphthalenes Chemical class 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 1
• WTFQBTLMPISHTA-UHFFFAOYSA-N octaphene Chemical compound C1=CC=C2C=C(C=C3C4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=CC3=C3)C3=CC2=C1 WTFQBTLMPISHTA-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 239000010502 orange oil Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 208000010713 partial hind limb paralysis Diseases 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
• SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
• GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
• JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C=C4C=CC3=CC2=C1 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• NQEDSLMJTARJAI-UHFFFAOYSA-N phenol;2h-triazole Chemical compound C1=CNN=N1.OC1=CC=CC=C1 NQEDSLMJTARJAI-UHFFFAOYSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 239000002985 plastic film Substances 0.000 description 1
• DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
• 238000009428 plumbing Methods 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 230000001144 postural effect Effects 0.000 description 1
• 229940068988 potassium aspartate Drugs 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 239000008057 potassium phosphate buffer Substances 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 1
• BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
• 229960001327 pyridoxal phosphate Drugs 0.000 description 1
• FDDQRDMHICUGQC-UHFFFAOYSA-M pyrrole-1-carboxylate Chemical compound [O-]C(=O)N1C=CC=C1 FDDQRDMHICUGQC-UHFFFAOYSA-M 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 210000003370 receptor cell Anatomy 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 230000028527 righting reflex Effects 0.000 description 1
• FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 1
• YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 208000020685 sleep-wake disease Diseases 0.000 description 1
• 239000012748 slip agent Substances 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000013517 stratification Methods 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 125000000542 sulfonic acid group Chemical group 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• FWMUJAIKEJWSSY-UHFFFAOYSA-N sulfur dichloride Chemical compound ClSCl FWMUJAIKEJWSSY-UHFFFAOYSA-N 0.000 description 1
• 125000004354 sulfur functional group Chemical group 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 238000004885 tandem mass spectrometry Methods 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• SOGXYCNKQQJEED-QMMMGPOBSA-N tert-butyl (2s)-2-(aminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CN SOGXYCNKQQJEED-QMMMGPOBSA-N 0.000 description 1
• DSXFEYYTYBXYMB-UHFFFAOYSA-N tert-butyl 4-(aminomethyl)piperidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CCC(CN)CC1 DSXFEYYTYBXYMB-UHFFFAOYSA-N 0.000 description 1
• GHFPCYDKHOYCOJ-UHFFFAOYSA-N tert-butyl 4-[(5-amino-1-oxoisoquinolin-2-yl)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1C(=O)C2=CC=CC(N)=C2C=C1 GHFPCYDKHOYCOJ-UHFFFAOYSA-N 0.000 description 1
• 239000012085 test solution Substances 0.000 description 1
• 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
• CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
• NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
• 125000004001 thioalkyl group Chemical group 0.000 description 1
• HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
• FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229940100611 topical cream Drugs 0.000 description 1
• 229940100615 topical ointment Drugs 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
• VOITXYVAKOUIBA-UHFFFAOYSA-N triethylaluminium Chemical compound CC[Al](CC)CC VOITXYVAKOUIBA-UHFFFAOYSA-N 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• LZGVDNRJCGPNDS-UHFFFAOYSA-N trinitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)[N+]([O-])=O LZGVDNRJCGPNDS-UHFFFAOYSA-N 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000011800 void material Substances 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1